Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis.
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002140:California; D002626:Chemistry, Pharmaceutical; D002990:Clobetasol / Q000008:administration & dosage* / Q000138:chemical synthesis; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000138:chemical synthesis; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000138:chemical synthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D003879:Dermatologic Agents; D005938:Glucocorticoids; D002990:Clobetasol